The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Veneto-STOP: MRD detection by NGS to optimize treatment outcomes with venetoclax
Undetectable measurable residual disease (uMRD) with venetoclax therapy is associated with improved PFS in patients with chronic lymphocytic leukemia (CLL). Chaitra Ujjani, MD, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, explains the rationale of utilizing MRD assessment with a next generation sequencing (NGS) assay in order to guide clinical decision making in patients with CLL that are receiving venetoclax-based regimens. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
